Tagged with Pharma,

Report PharmaBoardroom had the opportunity to sit down with over six hundred key stakeholders in the life sciences industry across fifteen different countries in 2019. The culmination of time spent in these countries and the insights gained from the interviews we conducted resulted in the publishing of thirteen country reports. Here…

Czech Republic Emmanuelle Boishardy joined GSK in France 20 years ago. In 2017, she embarked on her first assignment as General Manager – in the Czech affiliate. She recounts how she adapted to her new position in a foreign country and turned the affiliate around by overhauling compliance processes and successful launches…

Czech Republic Josef Kredba, country manager Czech Republic at G.L. Pharma, an Austrian pharmaceutical company, explains how the company has returned to growth in the challenging Czech generics market and shares his thoughts on market access and pricing conditions for both innovative and generic products.   On the one hand, authorities recognize…

Korea Multinational pharma company managers working abroad must adapt to new cultures and develop a deep understanding of local markets. Korea is no different; here three foreign country managers give their first impressions and insights into the Korean pharma market.   Nic Horridge, Roche   As a newcomer in the land…

Sweden Belying its small size, the Nordic nation of Sweden punches well above its weight in scientific innovation. Despite boasting a population of just 10 million and a marginal position on the most northerly fringes of the EU, Sweden has been ranked the second most innovative country in the world by…

Taiwan Long overshadowed by larger and more well-known neighbours, the island of Taiwan is nonetheless cultivating an enviable reputation at the forefront of some of the most innovative trends shaping global healthcare today.   From artificial intelligence to blockchain, the internet of things and regenerative medicine, Taiwanese firms – with the…

China PharmaBoardroom recently analysed the contents of 10 interviews conducted with country managers at multinational pharma companies in China. We found some underlying themes present in the majority of the interviews, giving an exclusive glimpse into what is currently at the top of the minds of pharma country managers in China.…

Czech Republic Martin Mátl, executive director of the Czech Association of Pharmaceutical Companies (ČAFF), shares the key priorities and challenges of the association and its members; assesses the Czech generics ecosystem, and gives insight into the importance of generics in providing a sustainable healthcare environment with ready availability of medicines for patients.…

Puerto Rico Based in Tampa, Florida, Romark is a research-based pharmaceutical company focused on developing innovative treatments for infectious diseases. The company recently inaugurated its first finished products manufacturing facilities in Puerto Rico, transforming itself into a vertically integrated organization. CEO Marc Ayers extols the strengths of Puerto Rico as manufacturing location…

Hungary Hungarian national champion Egis and French Big Pharma Sanofi have both made recent big-ticket investments in new facilities in Hungary. Egis’ new manufacturing plant in Körmend and Sanofi’s new shared service centre in Budapest respectively stand to have a sizeable impact on the local economies and show the increasing attractiveness…

Thailand PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Thailand is available for download now.   Thailand is in the midst of an economic transformation with healthcare at its heart. With four years of around three-four percent annual GDP growth behind it, ASEAN’s second-largest economy has implemented an ‘Industry 4.0’ policy through which…

GSK In conversation at the FT Global Pharmaceutical and Biotechnology Conference in London,* an energetic Emma Walmsley discussed the strategic and cultural shifts she has implemented in her two and a half years as CEO of iconic British firm GSK, the increasingly important intersection between technology and pharma, and countering the…